Since<unk>  is a syndrome associated with other diseases, treating the underlying disease may eventually reduce the symptoms of<unk> . Possible pharmacological interventions for<unk>  affect include the tricyclic antidepressants, serotonin reuptake inhibitors, and a novel approach utilizing dextromethorphan and quinidine sulfate. Nuedexta is an FDA approved medication for<unk>  affect. Dextromethorphan, an N-methyl-D-aspartate receptor antagonist, inhibits glutamatergic transmission in the regions of the brainstem and cerebellum, which are hypothesized to be involved in<unk>  symptoms, and acts as a sigma ligand, binding to the sigma-1 receptors that mediate the emotional motor expression.
Pseudobulbar palsy
Bulbar palsy
Trigeminal trophic syndrome
Subacute myelo-optic neuropathy
Trigeminal autonomic cephalgia
Todd's paresis
Central facial palsy
Cerebellopontine angle syndrome